- Home
- MDAI vs IMUX Comparison
MDAI vs IMUX Comparison
Compare MDAI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- IMUX
- Stock Information
- Founded
- MDAI 2013
- IMUX 2016
- Country
- MDAI United States
- IMUX United States
- Employees
- MDAI N/A
- IMUX N/A
- Industry
- MDAI Medical/Dental Instruments
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- MDAI Health Care
- IMUX Health Care
- Exchange
- MDAI Nasdaq
- IMUX Nasdaq
- Market Cap
- MDAI 69.0M
- IMUX 67.8M
- IPO Year
- MDAI N/A
- IMUX N/A
- Fundamental
- Price
- MDAI $2.44
- IMUX $0.87
- Analyst Decision
- MDAI Strong Buy
- IMUX Strong Buy
- Analyst Count
- MDAI 2
- IMUX 5
- Target Price
- MDAI $4.75
- IMUX $7.50
- AVG Volume (30 Days)
- MDAI 460.4K
- IMUX 1.1M
- Earning Date
- MDAI 08-12-2025
- IMUX 08-07-2025
- Dividend Yield
- MDAI N/A
- IMUX N/A
- EPS Growth
- MDAI N/A
- IMUX N/A
- EPS
- MDAI N/A
- IMUX N/A
- Revenue
- MDAI $29,962,000.00
- IMUX N/A
- Revenue This Year
- MDAI N/A
- IMUX N/A
- Revenue Next Year
- MDAI $15.15
- IMUX N/A
- P/E Ratio
- MDAI N/A
- IMUX N/A
- Revenue Growth
- MDAI 55.21
- IMUX N/A
- 52 Week Low
- MDAI $0.82
- IMUX $0.56
- 52 Week High
- MDAI $3.25
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- MDAI 49.07
- IMUX 44.49
- Support Level
- MDAI $2.34
- IMUX $0.89
- Resistance Level
- MDAI $2.55
- IMUX $1.01
- Average True Range (ATR)
- MDAI 0.17
- IMUX 0.08
- MACD
- MDAI -0.04
- IMUX -0.02
- Stochastic Oscillator
- MDAI 25.93
- IMUX 12.03
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.